Farmacokinetics and farmacodynamics of drugs used in neonates and children during Extracorporal Membanous Oxygenation (ECMO)

Phase 4

Completed

• Conditions: patienten aan ECMO; heart-lung machine

• Registration Number: NL-OMON30690
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

neonates and children 0-18 year on ECMO

Exclusion Criteria

Witheld informed consent

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Karacterizing the Pharmacokinetics of different drugs (analgesia, sedatives,<br /><br>antibiotics, inotropic agents, PGE5 inhibitor, and diuretics) routinely used in<br /><br>patients undergoing ECMO.<br /><br>Describing the relationship between pharmacokinetics and demografical,<br /><br>physiological, pathophysiological factors like diagnosis, genotype, PRISM/PIM<br /><br>scores, liver and kidney function<br /><br>albumin concentrations, different ECMO modi, ECMO flow, dialysis,<br /><br>bloodtransfusions and ventilator settings.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Karacterizing the relationship between pharmacokinetics and clinical effects of<br /><br>the above mentioned medication.<br /><br>Describing the relationship between pharmacodynamics and demografical,<br /><br>physiological, pathophysiological factors.<br /><br>Formulating dosing regimes for the studied medication for patients treated with<br /><br>ECMO.</p><br>